Implementation of a guideline for the treatment of pain, sedation, agitation and neuromuscular blockade in the mechanically ventilated adult patient in the emergency department

Kristin E White1
Paul M Szumita1
Nicki Gilboy2
Hillary A Keenan3
Christian Arbelaez2

1Department of Pharmacy Services,
2Department of Emergency Medicine,
3Center for Clinical Investigation,
Brigham and Women’s Hospital,
Boston, MA, USA

Purpose: When emergency department (ED) overcrowding includes admitted mechanically ventilated (MV) critically-ill patients without an open intensive care unit (ICU) bed, emergency providers must deliver ICU level care in the ED. Implementing standardized hospital based clinical guidelines may help providers achieve uniform care standards for assessing and managing pain and sedation for the MV patient.

Objective: This paper is a description of a hospital performance improvement project that was implemented in the ED. The objective of this study was to measure the degree of adoption of a hospital-wide clinical guideline for the management of pain, sedation and neuromuscular blockade in MV patients into clinical practice in the ED.

Methods: A retrospective analysis was performed for all mechanically ventilated patients who were admitted from ED to an Intensive Care Unit (ICU). Patient charts were reviewed before (December 2005) and after the implementation of the guideline (June, August, and December 2006). Data was collected and analyzed for the ED visit only and no ICU data was used. The primary outcome was the degree of adoption of the guideline by emergency providers into their daily clinical practice.

Results: A convenience sample of 170 adult MV patients who were admitted to the ICU during the preselected time period was analyzed. There were no demographic differences between groups of patients observed during each month interval, age ($P=0.34$), gender ($P=0.40$), race ($P=0.14$), and Hispanic ethnicity ($P=0.84$). Overall, there was an increase in the provider use of propofol ($P<0.01$), RASS sedation scale ($P<0.01$), and a decrease in the use of a paralytic agent ($P<0.01$).

Conclusion: There was partial adoption of a guideline into their clinical practice by emergency providers in a busy urban emergency department. Across the 12-month implementation period, there was improvement in the assessment of and use of analgesia and sedation for MV patients.

Keywords: clinical guideline, critical care, ICU, emergency department, sedation, pain, neuromuscular blocker

Purpose

An increase in the volume and acuity of patients presenting to the emergency department (ED) has led to significant strains on providers. When ED overcrowding includes admitted mechanically ventilated (MV) critically-ill patients without an open intensive care unit (ICU) bed, an added burden of significant importance lies on
emergency providers, who must deliver ICU level care in the ED. Implementing standardized hospital-based clinical guidelines may help providers achieve uniform care standards for assessing and managing pain and sedation for MV patients.1–4

The importance of providing optimal care for MV adult patients in the ICU has been well documented. The Society of Critical Care Medicine has published practice guidelines for MV patients centered around adequate assessment for and administration of analgesia, sedation, and periodic assessment with a validated tool to determine proper medication effect.5–16 Receiving too much or too little medication to manage pain or agitation may lead to adverse outcomes including: delirium; an increase in oxygen consumption; inadvertent removal of devices or catheters; increased risk of infection; and possible post-traumatic stress disorders.11,17–23 The emergency medicine literature has focused primarily on rapid sequence intubation and not on the management of the postintubated patient or the use of validated sedation assessment tools for appropriate medication titration to achieve the desired effect for patients while in the ED.

In response to concerns regarding inappropriate analgesia, sedation and use of paralytic agents in MV adult ED patients in our institution, a process improvement team was formed to evaluate the management and find ways to improve care for these patients. A multidisciplinary team was led by an emergency medicine attending physician and included the ED nursing manager, the ED nurse educator, ED staff nurse, an ICU clinical pharmacy specialist, and a pharmacy practice resident.

The process improvement team helped develop an evidence-based clinical guideline for the treatment of pain, agitation and neuromuscular blockade in MV adult patients in the hospital, including the ED and all ICUs (Figure 1). The algorithm addressed the following objectives: 1) providing adequate patient analgesia and reassessment with the Visual Analog Scale (VAS) for titration to effect; 2) providing adequate patient sedation and reassessment with the Richmond Agitation and Sedation Scale (RASS) for titration to effect; and 3) if providing paralysis, after adequate analgesia, sedation, and monitoring with RASS, the ED providers could additionally utilize the Bispectral Index (BIS) to ensure appropriate levels of sedation during paralysis. The objective of this study was to evaluate the degree of adoption of the hospital-wide guideline after implementation into clinical practice in the ED.

### Methods

#### Study design

This study was approved by the hospital investigational review committee. We conducted a retrospective chart review and analysis of all consecutive MV patients admitted to the ICU from the ED during the following four months: baseline (December 2005) and after each phase of implementation (June, August, and December 2006). A report of all patients admitted from the ED to an ICU for each of the four months was generated. A pharmacy practice resident reviewed all admitted patient charts and performed all data collection. An emergency medicine attending physician was available to answer all questions and clarify cases the reviewer had difficulty classifying. All patients who were MV and were at least eighteen years of age were included. No patients were excluded.

Our ED is a level-one trauma and major tertiary referral center with over 56,000 patient visits per year. On average, the hospital admission rate is about 25% with approximately 40 MV patients admitted to the hospital ICUs per month. Emergency providers were defined as attending physicians, residents, and nurses working in the ED during the study time period. All emergency providers were required to attend a mandatory education and training session which outlined the guideline recommendations for the management of MV patients with adequate analgesia, sedation, and paralysis.

The primary outcome measured was adoption of the guideline into clinical practice by emergency providers. We used the provider order entry (POE) system to obtain the percentage of medications ordered for analgesia, sedation, and paralysis, and the percentage of physician orders for the correct monitoring assessment tools (VAS, RASS, BIS). We used the patient’s critical care nursing flow sheet to obtain the percentage of medications that were actually administered for analgesia, sedation, and paralysis and whether or not one of the assessment scales was documented. Data collection occurred from the time the patient entered the ED and received care from the ED providers to the time the patient physically left the ED.

#### Statistics

All variables were examined for adherence to the normal distribution visually and by skewness and kurtosis statistics. Chi-square, Fisher’s exact test for categorical variables, and the Wilcoxon Rank Sum test for continuous variables were used for determining significant differences between groups. The Cochran-Armitage method was used to test for trends...
Assume patient is in pain
Goal: VAS score <2, no signs of pain

Hemodynamically compromised?

Yes

Fentanyl

No

Choose from
Fentanyl
Morphine
Hydromorphone

Sedation-agitation management
Goal: RASS* 0 to −1, BIS* Goal 60–80

Consider delirium

Choose from
Haloperidol
Olanzapine
Quetiapine

Goal RASS* Score 0 to −1

Neuro/head injury/need for frequent or rapid awakening or requiring angiography procedure?

Yes

Propofol

No

Choose from
Midazolam
Lorazepam

Neuromuscular blockade management
Is paralysis indicated in this patient?
Is patient at goal RASS* −4 to −5 and BIS* Goal 40–60

No

Yes

Choose from
Vecuronium
Cisatracurium
Pancuronium

REASSESS FREQUENTLY

Figure 1 Clinical algorithm for the hospital-wide guideline for the management of the mechanically vented adult patient.

Abbreviations: VAS, Visual Analog Scale; RASS, Richmond Agitation and Sedation Scale; BIS, Bispectral Index.
in the distribution of categorical variables across months, whereas, generalized linear regression was used to determine if there was a significant trend across the study period in continuous variables. All analyses were performed using SAS statistical software (v 9.1; SAS Institute, Inc, Cary, NC).

Results
A total of 170 patient charts were reviewed from the four month intervals (n = 46, 42, 42, and 40, respectively). The mean (±SD) age of our subjects was 57.9 (±19.2), 53% (n = 90) were female, 68% (n = 116) were white, and 93% (n = 157) were non-Hispanic. There were no demographic differences between groups of patients observed during each month interval (Table 1), for age (P = 0.34), gender (P = 0.40), race (P = 0.14), or Hispanic ethnicity (P = 0.84). The distribution of patients admitted across the different ICUs did not vary across the various months reviewed (% admissions: Medical 42%, Surgical 32%, and Neurological 26%).

Across the 12-month implementation period, there was a significant increase in the physician ordering of propofol for sedation (P-trend < 0.01; 0 at baseline to 20% in month 4) and nursing documentation of a RASS score in the patient’s critical care flow sheet (P-trend < 0.01). The administration of propofol greatly increased over the study with 33% of patients receiving the sedative during month 4 versus 0% in month 1. The largest increase in provider use of propofol occurred from month 1 (0%) to month 2 (24%) and was most likely related to the hospital approval of propofol continuous infusion for use in MV patients in the ED.

Across all time periods, the percentage of providers documenting the RASS for titration of sedation increased. After the introduction of the patient critical care flow sheet, which included a designated space for RASS documentation, the percentage of patients with a documented score increased by 10%. The documentation of a BIS score in the flow sheet had a trend toward significance (P-trend = 0.05) across all time points. Emergency providers also ordered and administered less neuromuscular blockade to patients after the introduction of the guideline. Paralytic administration declined over the study period, from 22% (n = 10) in month 1 to 8% (n = 3) in month 4 (P-trend = 0.06) (Table 2).

Discussion
This study demonstrates the partial adoption by emergency providers of a clinical guideline in an urban ED, with an improvement in the use of analgesia, sedation, and paralytics for MV patients. The main goal of the process improvement team was to improve care in the ED by ensuring that all MV patients received the same level of care in the ED and ICUs.

Table 1 Characteristics of subjects (n = 170)

<table>
<thead>
<tr>
<th></th>
<th>All % (n)</th>
<th>P-value</th>
<th>Baseline n = 46</th>
<th>Month 1 n = 42</th>
<th>Month 2 n = 42</th>
<th>Month 3 n = 40</th>
<th>P-trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs ± SD)</td>
<td>57.9 ± 19.2</td>
<td>0.47</td>
<td>57.9 ± 22.2</td>
<td>61.4 ± 18.0</td>
<td>53.8 ± 19.5</td>
<td>58.4 ± 16.2</td>
<td>0.98</td>
</tr>
<tr>
<td>Female</td>
<td>53 (90/170)</td>
<td>&lt;0.01</td>
<td>24</td>
<td>15</td>
<td>21</td>
<td>21</td>
<td>0.27</td>
</tr>
<tr>
<td>White</td>
<td>68 (116/170)</td>
<td>&lt;0.01</td>
<td>35</td>
<td>24</td>
<td>30</td>
<td>27</td>
<td>0.74</td>
</tr>
<tr>
<td>Non-Hispanic</td>
<td>93 (157/170)</td>
<td>&lt;0.01</td>
<td>43</td>
<td>40</td>
<td>37</td>
<td>37</td>
<td>0.60</td>
</tr>
<tr>
<td>Type of ICU</td>
<td></td>
<td>0.04</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical</td>
<td>42 (71/170)</td>
<td>0.04</td>
<td>19</td>
<td>18</td>
<td>18</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>Surgical</td>
<td>32 (55/170)</td>
<td></td>
<td>18</td>
<td>12</td>
<td>12</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Neurological</td>
<td>26 (44/170)</td>
<td></td>
<td>9</td>
<td>12</td>
<td>12</td>
<td>11</td>
<td></td>
</tr>
</tbody>
</table>
The most notable finding was the rapid adoption and increased use of the sedative propofol, a medication which had not been previously approved for use in the ED at our institution. We found that most ED providers preferentially used propofol due to its rapid titration ability, despite its designation as a second-line agent for most medical patients in the new algorithm.

We believe that the partial adoption can be attributed to the provider education and training sessions; the new physician order entry template; and the new patient critical care flow sheets that were rolled out clinically with the guideline. For the educational component, the physicians and nurses were given a survey to assess baseline medical knowledge regarding the care of the MV patient. Didactic education and training sessions were then designed and delivered to the emergency providers’ needs.

The clinical adjunct tools (physician order entry template and patient critical care flow sheet) were helpful real-time reminders to prompt assessment, documentation and medication titration relative to the VAS, RASS and BIS scales. Despite these tools, changes in clinical practice often take time, resources, and provider buy-in before clinical adoption occurs.

Several trials have assessed the implementation of pain, sedation and delirium monitoring in the ICU; however, to the authors’ knowledge this is one of the first attempts at describing and assessing the management of MV patients in the ED. A recent review of the general care of MV patients in the ED has been published emphasizing the importance of extending ICU care standards to MV patients boarding in the ED. This review has further emphasized the need for ED providers to conform to current ICU practice standards to reduce morbidity and mortality of MV ED patients. The authors believe that the same care goals set by the Society of Critical Care medicine for assessing and treating MV patients’ pain and level of sedation may be applied universally to MV ED patients.

Other studies have investigated the implementation of sedation assessment of ICU patients with good adherence. Compared with a previous guideline implementation study in an ICU setting, our partial adoption of the guideline is less robust, but our observations and challenges faced are similar to what others have described as key components in implementing any protocol in the clinical setting. These critical elements include having clinical champions and evidence-based guidelines that are clear and easy to use, especially in a large urban setting where there are many rotating patient care providers. These clinical champions are either a single person, or more often, a small group of clinicians willing to accept the responsibility to model and encourage a positive change in clinical practice. Clinical pharmacists were not physically present in the ED at the time of our study but may be well positioned to become a part of such efforts in process improvement projects that occur in

### Table 2 Adoption of guideline components by emergency providers (n = 170)

<table>
<thead>
<tr>
<th></th>
<th>Baseline n = 46</th>
<th>Month 1 n = 42</th>
<th>Month 2 n = 42</th>
<th>Month 3 n = 40</th>
<th>P-value</th>
<th>All n = 170</th>
<th>P-trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analgesia POE Y</td>
<td>20 (43)</td>
<td>23 (55)</td>
<td>23 (55)</td>
<td>23 (58)</td>
<td></td>
<td>89</td>
<td></td>
</tr>
<tr>
<td>Analgesia documented Y</td>
<td>23 (50)</td>
<td>23 (55)</td>
<td>31 (74)</td>
<td>25 (63)</td>
<td>0.60</td>
<td>81</td>
<td>0.22</td>
</tr>
<tr>
<td>Sedation POE Y</td>
<td>20 (43)</td>
<td>26 (62)</td>
<td>23 (55)</td>
<td>20 (50)</td>
<td></td>
<td>89</td>
<td></td>
</tr>
<tr>
<td>Sedation documented Y</td>
<td>26 (57)</td>
<td>16 (38)</td>
<td>19 (45)</td>
<td>20 (50)</td>
<td>0.34</td>
<td>81</td>
<td>0.59</td>
</tr>
<tr>
<td>Propofol POE Y</td>
<td>0 (0)</td>
<td>9 (21)</td>
<td>9 (21)</td>
<td>8 (20)</td>
<td></td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>Propofol documented Y</td>
<td>46 (100)</td>
<td>33 (79)</td>
<td>33 (79)</td>
<td>32 (80)</td>
<td>&lt;0.01</td>
<td>144</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Paralytic POE Y</td>
<td>7 (15)</td>
<td>2 (5)</td>
<td>3 (7)</td>
<td>4 (10)</td>
<td></td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>Paralytic documented Y</td>
<td>39 (85)</td>
<td>40 (95)</td>
<td>39 (93)</td>
<td>36 (90)</td>
<td>0.40</td>
<td>154</td>
<td>0.35</td>
</tr>
<tr>
<td>RASS documented Y</td>
<td>10 (22)</td>
<td>2 (5)</td>
<td>6 (14)</td>
<td>3 (8)</td>
<td></td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>BISS documented Y</td>
<td>36 (76)</td>
<td>40 (95)</td>
<td>36 (86)</td>
<td>37 (93)</td>
<td>0.85</td>
<td>149</td>
<td>0.06</td>
</tr>
<tr>
<td>N</td>
<td>46 (98)</td>
<td>32 (76)</td>
<td>34 (81)</td>
<td>27 (67)</td>
<td>&lt;0.01</td>
<td>139</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

**Abbreviations:** N, no; POE, provider order entry; Y, yes.
the ED. As ED-based pharmacists increase, there is a clear opportunity for pharmacists to lead these efforts within a multidisciplinary team. Dedicated clinical pharmacists now cover our ED full-time, and are available to give providers real-time feedback in their use of the guideline and management of MV patients.\textsuperscript{10}

**Limitations**

The results of this study should be interpreted in the context of its limitations. Firstly, this was a single-center retrospective chart review that was not powered a priori for the primary outcomes. It captured adherence with the guideline rather than incidence or ability of achieving the clinical goals as set out by the guideline, as adherence was accepted if there was a single order or recording for each category measured instead of a true assessment of outcomes. We were unable to differentiate between occurrence and patient satisfaction or percentage of time at goal. Patients’ satisfaction and comfort was not directly assessed. Some of the documented metrics are suboptimal and may be reflective of new practice changes. Also, our results show more sedation administered by the nurses than what was actually ordered by the physician, which may be attributed to verbal orders. The development and implementation of a hospital-wide guideline require a clinical champion, provider buy-in, adequate resources, education and training sessions, and protocol-based clinical adjuncts. Future projects should focus on a prospective evaluation of clinical outcomes and the impact of ED-based pharmacists in clinical practice guideline adherence.

**Conclusion**

As more acutely-ill patients are being cared for and boarded in the ED, the care of the MV patient should be standard across the hospital, including the ED and ICUs. We have developed and implemented an evidence-based algorithm coupled with clinical adjuncts that prompt providers to use it in clinical practice. In our busy urban ED, there was partial adoption by emergency providers of our hospital-wide guideline. Continued efforts are needed to further enhance our guideline adoption. Clinical pharmacists specializing in emergency medicine have a clear opportunity to participate in multidisciplinary efforts in developing, implementing, and monitoring such clinical guidelines.

**Disclosure**

Kristin White, Paul Szumita, Nicki Gilboy, Hilary Keenan and Christian Arbelaez have no affiliation with the manufacturers of any of the products mentioned in the paper.

**References**


